Advancing Hepatitis B Innovation: Highlights From The 2025 International Hepatitis B Meeting

By Tea Kakabadze, MD, Ph.D., Associate Medical Director, Novotech

The International Hepatitis B Meeting in Berlin (September 8–11, 2025) brought together the global HBV and HDV community — from scientists and clinicians to biotech leaders and patient advocates — for four days of deep scientific exchange and clinical insight. Discussions spanned the full spectrum of hepatitis research, from epidemiological shifts and evolving treatment guidelines to cutting-edge immune and virologic discoveries shaping the next generation of therapies.

Early sessions highlighted how expanded screening and updated EASL guidance are driving earlier diagnosis and broader treatment eligibility, with a growing focus on patient experience and real-world access. Later presentations delved into molecular mechanisms of persistence and clearance, new therapeutic classes such as RNA interference agents and capsid modulators, and promising data from emerging combination and immune-restorative approaches.

For clinical developers, the message was consistent: success in this fast-moving field will rely on integrating translational science, global trial design, and patient-centered outcomes to turn promising discoveries into functional cures.